Clinical and molecular aspects of glucocorticoid resistant asthma

Therapeutics and Clinical Risk Management

Volumn 3, Issue 5, 2007, Pages 771-787

  Corrigan, Chris J ^a,b   Loke, Tuck Kay ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; COLECALCIFEROL; CORTICOSTEROID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; DNA; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; GROWTH FACTOR; HISTONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 5 ANTIBODY; ISOPROTEIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DRUG BINDING SITE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSCRIPTION INITIATION;

EID: 36448973136     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Adcock IM, Lane SJ, Brown CR, et al. 1995. Defective binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol, 154:3500-5.
2. Adcock IM, Lane SJ, Brown CR, et al. 1995. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med, 182:1951-8.
3. Akbari O, DeKruyff RH, Umetsu DT. 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunol, 2:725-31.
4. Alexander AG, Barnes NC, Kay AB. 1992. Trial of cyclosporine in corticosteroid-dependent chronic severe asthma. Lancet, 339:324-8.
5. Alvarez J, Surs W, Leung DYM et al. 1992. Steroid resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol, 89:714-21.
6. American Thoracic Society. 2000. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations and unanswered questions. Am J Respir Crit Care Med, 162:2341-51.
7. Bertos NR, Wang AH, Yang XJ. 2001. Class II histone deacetylases: structure, function and regulation. Biochem Cell Biol, 79:243-52.
8. Bledsoe RK, Montana VG, Stanley TB, et al. 2002. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerisation and coactivator recognition. Cell, 110:93-105.
9. Borish L, Aarons A, Rumbyrt J, et al. 1996. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol, 97:1288-96.
10. Buist SA. 1995. Cost effectiveness of asthma management strategies. Eur Respir Rev, 5:292-4.
11. Bumbacea D, Campbell D, Nguyen L, et al. 2004. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J, 24:122-8.
12. Busse PJ, Wang JJ, Halm EA. 2005. Allergen sensitization evaluation and allergen avoidance education in inner-city adult cohort with persistent asthma. J Allergy Clin Immunol, 116:146-52.
13. Carmichael J, Paterson IC, Diaz P, et al. 1981. Corticosteroid resistance in chronic asthma. Br Med J, 282:1419-22.
14. Chaudhuri R, Livingston E, McMahon AD et al. 2003. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med, 168:1308-11.
15. Clark TJH, Hetzel MR. 1977. Diurnal variation of asthma. Br J Dis Chest, 71:87-92.
16. Cochrane GM. 1992. Therapeutic compliance in asthma: its magnitude and implications. Eur Respir J, 5:122-4.
17. Cockcroft DW, Swystun VA. 1996. Asthma control versus asthma severity. J Allergy Clin Immunol, 98:1016-18.
18. Cookson W, Moffatt M. 2004. Making sense of asthma genes. N Engl J Med, 351:1794-6.
19. Corren J, Adinoff AD, Buchmeier AD, et al. 1992. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol, 90:250-6.
20. Corrigan CJ, Brown PH, Barnes NC, et al. 1991a. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics and inhibition of peripheral blood T-cell proliferation by glucocorticoids in vitro. A Rev Respir Dis, 144:1016-25.
21. Corrigan CJ, Brown PH, Barnes NC, et al. 1991b. Glucocorticoid resistance in chronic asthma: peripheral blood T-lymphocyte activation and a comparison of the T-lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am Rev Respir Dis, 144:1026-32.
22. Corrigan CJ, Kay AB. 1992. The role of T lymphocytes and eosinophils in the pathogenesis of asthma. Immunol Today, 13:501-7.
23. Corrigan CJ, Hamid Q, North J, et al. 1995. Peripheral blood CD4 but not CD8 T-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a TH2-type pattern: effect of glucocorticoid therapy. Am J Respir Cell Mol Biol, 12:567-78.
24. English JM, Cobb MH. 2002. Pharmacological inhibitors of MAPK pathways. Trends in Pharmacological Sciences, 23:40-5.
25. Demoly P, Jaffuel D, Mathieu M, et al. 1998. Glucocorticoid insensitive asthma: a one-year clinical follow up pilot study. Thorax, 53:1063.
26. Ding XF, Anderson CM, Ma H, et al. 1998. Nuclear receptor-binding sites of coactivators glucocorticosteroid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol, 12:302-13.
27. Dolan CM, Fraher KE, Bleecker ER et al. 2004. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol, 92:32-9.
28. ENFUMOSA. 2003. The ENFUMOSA cross-sectional European multicentre study of the clinical phnotype of chronic severe asthma. Eur Respir J, 22:470-7.
29. Flood-Page P, Menzies-Gow A, Phipps S, et al. 2003. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest, 112:1029-36.
30. Franchimont D, Martens M, Hagelstein MT, et al. 1999. Tumour necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrin Metab, 84:2834-9.
31. Haczku A, Alexander A, Brown P, et al. 1994. The effect of dexamethasone, cyclosporine and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. J Allergy Clin Immunol, 93:510-19.
32. Hahn DL, Dodge RW, Golubjatnikov R. 1991. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset. JAMA, 266:225-30.
33. Hakonarson H, Bjornsdottir US, Halapi E, et al. 2005. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA, 102:14789-94.
34. Hall IP. 1998. Genetic factors in asthma severity. Clin Exp Allergy, 28(5 Suppl): 16-20.
35. Hamid QA, Wenzel SE, Hank PJ, et al. 1999. Increased glucocorticoid receptor β in airway cells of glucocorticoid-insensitive asthma. Am J Respir Crit Care Med, 59:1600-4.
36. Hauk PJ, Wenzel SE, Trumble AE, et al. 1999. Increased T-cell receptor vbeta8+ T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: a potential role for microbial superantigens. J Allergy Clin Immunol, 104:37-45.
37. Hauk PJ, Hamid QA, Chrousos GP, et al. 2000. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol, 105:782-7.
38. Hawrylowicz CM, Richards DF, Loke T-K, et al. 2002. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid resistant asthmatic patients. J Allergy Clin Immunol, 109:369-70.
39. Heaney LG, Conway E, Kelly C, et al. 2003. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax, 58:561-6.
40. Hittelman AB, Burakov D, Iniguez-Lluki JA, et al. 1999. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J, 18:5380-8.
41. Hurley DM, Accili D, Stratakis CA, et al. 1991. Point mutation causing a single amino acid substitution in the hormone-binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest, 87:680-6.
42. Imhof A, Wolffe AP. 1998. Transcription: gene control by targeted histone acetylation. Curr Biol, 8:R422-4.
43. Irusen E, Matthews JG, Takatiashi A, et al. 2002. MAP kinase-induced glucocorticoid-receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J. Allergy Clin Immunol, 109:649-57.
44. Ito K, Barnes PJ, Adcock IM. 2000. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol, 20:6891-903.
45. Ito K, Ito M, Elliott WM, et al. 2005. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Eng J Med, 352:1967-76.
46. Ito K, Chung KF, Adcock IM. 2006. Update on glucocorticoid action and resistance. J Allergy Clin Immunol, 117:522-43.
47. Janknecht R, Hunter T. 1996. Versatile molecular glue: transcriptional control. Curr Biol, 6:951-4.
48. John M, Lim S, Seybold J, et al. 1998. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-lalpha, granulocyte-macrophage colony-stimulating factor and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med, 157:256-62.
49. Kam JC, Szefler SJ, Surs W, et al. 1993. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol, 151:3460-6.
50. Kamada AK, Leung DYM, Szefler SJ. 1992. Steroid resistance in asthma: our current understanding. Pediatr Pulmonol, 14:180-6.
51. Kamada AK, Szefler SJ, Leung DYM. 1993. The growing problem of steroid resistant asthma. Drug Ther, 23:55-68.
52. Kamei Y, Xu L, Heinzel T, et al. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell, 85:403-14.
53. Katsoulis K, Kontakiotis T, Leonardopoulos I, et al. 2003. Serum total antioxidant status in severe exacerbation of asthma: correlations with the severity of the disease. J Asthma, 40:847-54.
54. Kelloway IS, Wyatt RA, Adlis SA. 1994. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med, 154:1349-52.
55. Kharitonov SA, Barnes PJ. 2003. Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Curr Allergy Asthma Rep, 3:121-9.
56. Kibe A, Inoue H, Fukuyama S, et al. 2003. Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. Am J Respir Crit Care Med, 167:50-6.
57. Kikuchi Y, Okabe S, Tamura G, et al. 1994. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med, 330:1329-34.
58. Kino T, Chrousos GP. 2001. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J Endocrinol, 169:437-45.
59. Klaustermeyer WB, Noritake DT, Kwong FK. 1987. Chrysotherapy in the treatment of corticosteroid-dependent asthma. J Allergy Clin Immunol, 79:720-5.
60. Krstic MD, Rogatsky I, Yamamoto KP, et al. 1997. Mitogen-activated and cyclin-dependent kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol Cell Biol, 17:3947-54.
61. Lamberts SWJ, Huizenga ATM, de Lande P, et al. 1996. Clinical aspects of glucocorticoid sensitivity. Steroids, 147:690-6.
62. Lane SJ, Arm JP, Staynov DZ, et al. 1994. Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Respir Cell Mol Biol, 11:42-8.
63. Lane SJ, Adcock IM, Richards D, et al. 1998. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest, 102:2156-64.
64. Lassalle P, Delneste Y, Gosset P, et al. 1993. T and B-cell immune response to a 55 kDa endothelial cell-derived antigen in severe asthma. Eur J Immunol, 23:796-803.
65. Lee TH, Brattsand R, Leung D. 1996. Corticosteroid action and resistance in asthma. Am J Respir Crit Care Med, 154:S51.
66. Lee W, Mitchell P, Tjian R. 1987. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell, 49:741-52.
67. Leung DY, Martin RJ, Szefler SJ, et al. 1995. Dysregulation of interleukin 4, interleukin-5 and interferon gamma gene expression in steroid-resistant asthma. J Exp Med, 181:33-40.
68. Leung DY, Bloom JW. 2003. Update on glucocorticoid action and resistance. J Allergy Clin Immunol, 111:3-22.
69. Li LB, Goleva E, Hall CF, et al. 2004. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol, 114:1059-69.
70. Lim S, Crawley E, Woo P, et al. 1998. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet, 352:113.
71. Lock SH, Kay AB, Barnes NC. 1996. Double-blind, placebo-controlled study of cyclosporine A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. J Allergy Clin Immunol, 153:509.
72. Loke TK, Mallett KH, Ratoff J, et al. 2006. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glueocorticoid-resistant asthmatic patients. J Allergy Clin Immunol, 118:368-75.
73. Milgrom H, Bender B, Ackerson L, et al. 1996. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol, 98:1051-7.
74. Miller BD, Strunk RC. 1989. Circumstances surrounding the deaths of children due to asthma. A case-control study. Am J Dis Child, 143:1294-9.
75. Miller MK, Johnson C, Miller DP, et al. 2005. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol, 116:990-5.
76. Moore KW, de Waal Malefyt R, Coffman RL, et al. 2001. IL-10 and the IL-10 receptor. Annu Rev Immunol, 19:683-765.
77. Nahm DH, Lee YE, Yim EJ, et al. 2002. Identification of cytokeratin 18 as a bronchial epithelial autoantigen associated with no allergic asthma. Am J Respir Crit Care Med, 165:1536-9.
78. National Institutes of Health. 1995. NHLB/WHO Workshop Report. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention: No. 95-3659. p. 1-176.
79. Newman KB, Mason UG, Schmaling KB. 1995. Clinical features of vocal cord dysfunction. Am J Respir Crit Care Med, 152:1382-6.
80. Nimmagadda SR, Szefler SJ, Spahn JD, et al. 1997. Allergen exposure decreases glucocorticoid receptor binding affinity and seroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med, 155:87-93.
81. Oakley RH, Sar M, Cidlowski JA. 1996. The human glucocorticoid receptor β isoform: expression, biochemical properties, and putative function. J Biol Chem, 271:9550-9.
82. Oakley RH, Jewell CM, Yudt MR, et al. 1999. The dominant negative activity of the human glucocorticoid receptor β isoform. J Biol Chem, 274:27857-66.
83. Pazin MJ, Kadonaga JT. 1997. What's up and down with histone deacetylation and transcription? Cell, 89:325-8.
84. Poznansky MC, Gordon ACH, Douglas JG, et al. 1984. Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patient, Clin Sci, 67:639-45.
85. Rabe KF, Adachi M, Lai CK, et al. 2004. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol, 114:40-7.
86. Reichhardt HM, Tuckermann JP, Gottlicher M, et al. 2001. Repression of inflammatory responses in the absence of DNA bind ng by the glucocorticoid receptor. EMBO J, 20:7168-73.
87. Richards DF, Fernandez M, Caulfield J, et al. 2000. Glucocorticoids drive human CD8+ T cell differentiation towards a phenotype with high IL-10 and reduced IL4, IL-5 and IL-13 production. Eur J Immunol, 30:2344-54.
88. Robinson DS, Hamid Q, Ying S, et al. 1993. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5 and interferon-gamma cytokine gene expression. Am Rev Respir Dis, 148:402-6.
89. Robinson DS, Campbell DA, Durham SR, et al. 2003. Systematic assessment of difficult-to-treat asthma. Eur Respir J, 22:478-83.
90. Rogatsky I, Logan SK, Garabedian MI. 1998. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc Natl Acad Sci USA, 95:2050-5.
91. Schwartz HL, Lowell FC, Melby JC. 1968. Steroid resistance in bronchial asthma. Ann Intern Med, 69:493-9.
92. Sher ER, Leung DM, Surs W, et al. 1994. Steroid-resistant asthma cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest, 93:33-9.
93. Shiner RJ, Nunn AJ, Chung KF, et al. 1990. Randomised, double-blind, placebo-controlled trial of methotrexate in steroid-dependent asthma. Lancet, 336:137-40.
94. Silkoff PE, Lent AM, Busacker AA, et al. 2005. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol, 116:1249-55.
95. Sousa AR, Lane SJ, Cidlowski JA, et al. 2000. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allerg Clin Immunol, 105:943-50.
96. Spahn JD, Leung DY, Surs W, et al. 1995. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med, 151:1709-14.
97. Spahn JD, Szefler SJ, Surs W, et al. 1996. A novel action of IL-13: induction of reduced monocyte glucocorticoid receptor-binding affinity. J Immunol, 157:2654-9.
98. Spahn JD, Leung DY, Szefler SJ. 1997. New insights into the pathogenesis and management of steroid-resistant asthma. J Asthma, 34:177-94.
99. Spaulding HS Jr, Mansfield LE, Stein MR, et al. 1982. Further investigation of the association between gastro-oesophageal reflux and bronchoconstriction. J Allergy Clin Immunol, 69:516-21.
100. Strickland I, Kisich K, Hauk PJ, et al. 2001. High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med, 193:585-94.
101. Szapary D, Huang Y, Simons SS. 1999. Opposing effects of corepressors and coactivators in determining the dose-response curve of agonists, and residual agonist-activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol Endocrinol, 13:2108-21.
102. ten Brinke A, Zwinderman AH, Sterk PJ, et al. 2004. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med, 170:601-5.
103. ten Brinke A, Sterk PJ, Masclee AA, et al. 2005. Risk factors of frequent exacerbations in diffiult-to-treat asthma. Eur Respir J, 26:812-18.
104. Wan S, DeSmet JM, Antoine M, et al. 1996. Steroid administration in heart and heart-lung transplantation: is the timing adequate? Ann Thoracic Surg, 61:674-8.
105. Wang CY, Bassuk AG, Boise LH, et al. 1994. Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-I and AP-1 transcription factors. Mol Cell Biol, 14:1153-9.
106. Wareham NJ, Harrison BD, Jenkins PF, et al. 1993. A district confidential enquiry into deaths due to asthma. Thorax, 48:1117-20.
107. Webster JC, Oakley RH, Jewell CM, et al. 2001. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β-isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA, 98:6865-70.
108. Wenzel SE, Szefler SJ, Leung DY, et al. 1997. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med, 156:737-43.
109. Wenzel SE, Schwartz LB, Langmack EL, et al. 1999. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med, 160:1001-8.
110. Woolcock AJ. 1993. Steroid-resistant asthma: what is the clinical definition? Eur Respir J, 6:743-7.
111. Xystrakis E, Kusumakar S, Boswell S, et al. 2006. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest, 116:146-55.
112. Yamada K, Elliott WM, Hayashi S, et al. 2000. Latent adenoviral infection modifies the steroid response in allergic lung inflammation. J Allergy Clin Immunol, 106:844-51.